Axonics Inc.
Company Snapshot
Company Overview
Founded in 2012, Axonics is a medical technology company. It is commercializing its r-SNM system (sacral neuromodulation system), which received FDA approval in 2019 to treat fecal incontinence and urinary retention and the symptoms of overactive bladder. The r-SNM the system is also approved in Europe, Canada and Australia. The company has been selling its r-SNM System in some European countries since 2018. In the U.S., it began commercially selling the r-SNM System in 2019. The r-SNM system takes advantage of Axonics’s proprietary SmartMRI technology, making it compatible with 3T MRI scan.
In February 2021, Axonics acquired Contura Ltd., the developer of Bulkamid, a non-particulate hydrogel injection to treat female stress urinary incontinence (SUI). Bulkamid had received FDA approval in 2020. The deal expanded Axonics’s portfolio of incontinence solutions portfolio.
In March 2022, the company received FDA approval of a recharge-free version of its SNM system.
Axonics Inc. In News
Company's Business Segments
- Medical Products and Theraphy : The company offers products and therapies to treat adults with bladder and bowel dysfunction.
Applications/End User Industries
- Overactive Bladder (OAB)
- Fecal Incontinence (FI)
- Urinary Retention (UR)
- Stress Urinary Incontinence (SUI)
